Journal
CURRENT ISSUES IN MOLECULAR BIOLOGY
Volume 45, Issue 7, Pages 5575-5597Publisher
MDPI
DOI: 10.3390/cimb45070352
Keywords
melanoma; molecular biology; genetics; clinical implications
Categories
Ask authors/readers for more resources
Most young patients with advanced skin tumors die from melanoma, but modern treatments have improved survival rates. However, managing advanced stage melanoma remains difficult due to the lack of long-lasting response to initial treatment and the absence of randomized clinical trials in post immunotherapy/targeted molecular therapy settings.
Almost every death in young patients with an advanced skin tumor is caused by melanoma. Today, with the help of modern treatments, these patients survive longer or can even achieve a cure. Advanced stage melanoma is frequently related with poor prognosis and physicians still find this disease difficult to manage due to the absence of a lasting response to initial treatment regimens and the lack of randomized clinical trials in post immunotherapy/targeted molecular therapy settings. New therapeutic targets are emerging from preclinical data on the genetic profile of melanocytes and from the identification of molecular factors involved in the pathogenesis of malignant transformation. In the current paper, we present the diagnostic challenges, molecular biology and genetics of malignant melanoma, as well as the current therapeutic options for patients with this diagnosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available